Proxim Diagnostics

About Proxim Diagnostics

Proxim Diagnostics Corp., founded in 2009 by Mikhail Briman and Vikram Joshi, is a key player in the point-of-care diagnostics market. The company is focused on the development of a handheld, portable immunoanalyzer, the Profile System, designed to deliver laboratory-grade results for critical tests directly to clinicians. This is achieved using whole blood samples, aiming to provide high sensitivity and precision without the delays of central lab testing. The business model appears to be centered on the sale of these handheld devices and the associated disposable, low-cost testing cartridges. The company targets healthcare settings where rapid diagnostics are crucial, such as emergency rooms, intensive care units, and remote clinics.

The co-founders' backgrounds are complementary to the company's mission. Mikhail Briman, the CEO, holds a Ph.D. in Physics from UCLA and has a history of inventing and developing sensor technologies with a focus on affordability and usability. Vikram Joshi brings expertise in advanced materials and their applications, holding an MBA from Wharton and an M.S. from Stanford. Their combined expertise drives the development of Proxim's core technology.

The Profile System is a battery-operated device featuring a touchscreen interface and multiple connectivity options. Its key value proposition is the ability to run a variety of multiplexed assays from a single disposable cartridge, with tests in development for sepsis, cardiology, and infectious diseases, including COVID-19 and Influenza A/B. The company's main research focuses are on infectious and cardiovascular diseases. Proxim has successfully raised a total of $22.9M through several funding rounds, including a significant strategic investment from diagnostics leader bioMérieux in March 2023. This investment is intended to finalize the development and commercialization of the Profile System, which is currently available for research use only.